Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Aug 13, 2022 11:19am
159 Views
Post# 34893926

RE:Knights Loans

RE:Knights Loans
EbbFlow88 wrote: I can't remember but I think the number of loans has decreased. Seems like they have been letting them run off and not renewing. 

The Synergy loan is maturing in 2022 and 60 degree pharma and M8 in 2023. That would be about $24M in proceeds to redirect to M&A. 

They already said they will not be investing in any new funds but does anyone have any ideas about loans?


I think they would still entertain loans but Samira is interested in real collateral (e.g. Samira wasn't interested in the Appili deal for that reason but Loadzone Holdings was).
As a one-stop-shop for young and upcoming drug developers, I think there is always room for negotiation and to offer cash as a loan or cash for ownership rights.  Many factors at play in the final deal decisions
<< Previous
Bullboard Posts
Next >>